GlassScriptPhysician profile
Dustin R Baker
NPI 1154360436
$5,419.52
in general payments reported to CMS, 2019-2025
49 companies · $879 in 2025
The $879 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $517 · 2021: $985 · 2022: $711 · 2023: $661 · 2024: $1,103 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $647.99 | 2019-2025 | |
| Abbvie INC. | $562.86 | 2021-2025 | Ubrelvy, Vraylar |
| Glaxosmithkline, LLC. | $554.82 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $540.55 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $533.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $262.89 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $218.17 | 2022-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Astellas Pharma US INC | $207.88 | 2019-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.36 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Dexcom, INC. | $166.35 | 2021-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $96.57 | 2021-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Supernus Pharmaceuticals, INC. | $89.62 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $79.96 | 2019-2021 | |
| Horizon Therapeutics Plc | $76.49 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $75.31 | 2022-2024 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Baker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.